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Background. Fluoroquinolone resistant Escherichia coli isolates 
have become an important challenge in healthcare settings in 
Iran. In this study, we have determined Fluoroquinolone resistant 
E. coli isolates (from both outpatients and inpatients) and evalu-
ated mutations of gyrA and parC within the quinolone resistance-
determining regions (QRDR) of these clinical isolates. 
Materials and methods. Clinical isolates were recovered from 
the urine sample of patients with urinary tract infections admit-
ted at Alzahra hospital, Iran, between September and February 
2013. We assessed antimicrobial susceptibility of all isolates and 
determined mutations in QRDR of gyrA and parC genes from 13 
fluoroquinolone-resistant isolates by DNA sequencing. 
Results. A total of 135 E. coli strains were obtained from 135 patients 
(91 outpatients and 44 inpatients). The resistance rate of fluoroqui-
nolones (Ciprofloxacin, Norfloxacin and Ofloxacin) among our 
strains was 45.2%. Two E. coli isolates were shown just a single 
mutation, but other isolates possessed 2-5 mutations in gyrA and 
parC genes. Mutations in the QRDR regions of gyrA were at posi-
tions Ser83 and Asp87 and parC at positions Ser80, Glu84, Gly78. 
Conclusions. Ciprofloxacin is the most common antimicrobial 
agent used for treating urinary tract infections (UTIs) in health-
care settings in Iran. Accumulation of different substitutions in the 
QRDR regions of gyrA and parC confers high-level resistance of 
fluoroquinolones in clinical isolates.
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Introduction
Urinary tract infections (UTIs) are one of the most fre-
quent bacterial infections around the world that almost 
occurs in the healthcare setting [1]. UTIs are the sec-
ond most common type of infections in the human that 
poses a serious health problem because of the antibi-
otic resistance and high recurrence rates. The available 
data shows that 150 million cases of UTIs occur on a 
global basis per year, resulting in more than 6 billion 
dollars in treatment costs  [2]. Uropathogenic Esch-
erichia coli (UPEC) is the essential cause of UTIs, 
including both cystitis and pyelonephritis and are re-
sponsible for more than 80% of these infections [3, 4]. 
It is supposed to, the pathogenic potential of UPEC 
isolates is dependent on a multitude of virulence fac-
tors (VFs) located on chromosome regions, referred 
to “pathogenicity islands” (PAIs) [3]. These different 
virulence factors promote colonization and infection 
of urinary tract [2]. 
Due to the complications of urinary tract infections, 
well-timed treatment of these infections has special im-
portance and treatment often accomplish based on the 
most prevalent pathogenic bacteria [5]. First, quinolones 
were introduced with nalidixic acid in 1962 for the treat-
ment of UTIs. In five decades, different generations of 
quinolones have introduced for clinical use. Since it was 
specified that fluoroquinolones have more potency than 
older quinolones, therefore use of these expanding class-
es of antimicrobial agents increased significantly  [6]. 
Fluoroquinolones are essential antimicrobial agents 
used to treat UTIs  [7]. Ciprofloxacin is the most fre-
quently used fluoroquinolone for the treatment of UTIs 
in healthcare settings, because of its availability in oral 
and intravenous formulations [8, 9]. 
Quinolones act via inhibition of DNA synthesis by pro-
moting cleavage of bacterial DNA in the DNA-enzyme 
complexes of DNA gyrase and type IV topoisomerase, 
resulting in rapid bacterial death [10]. Clinical experience 
has shown diverse antibiotic resistance among uropatho-
gens [11-13]. The increased use of fluoroquinolones has 
caused a remarkable emergence of resistance that varies 
by both organism and geographic region [6]. This resis-
tance commonly is the consequence of mutations involv-
ing genes encoding gyrA and parC [14]. In E. coli, alter-
nation at positions Ser-83 or Asp-87 in gyrA and Ser-80 
and Glu-84 in parC are the most frequent mutations [15]. 
The other substitutions are rare in clinical isolates [16]. 
The aim of this study was to determine the patterns of 
antimicrobial resistance and the presence of mutations 
in quinolone resistance coding regions in gyrA and parC 
in clinical isolates of E. coli from a hospital in Isfahan, 
Iran.
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Methods
Data collection
In order to describe the demographic and clinical char-
acteristics of patients with urinary tract infections, ad-
mitted patients were selected. Due to lack of access to 
inpatients, a permission was reached to access the inpa-
tient files. The final results were summarized after care-
ful examination of the files. 
Bacterial isolates
All clinical isolates were recovered from 135 consecu-
tive and not repetitive urine specimens of patients (91 
outpatients and 44 inpatients) with urinary tract infec-
tions admitted at Alzahra hospital, Isfahan, Iran, be-
tween September and February 2013. Diagnosis of E. 
coli isolates have done according to Bailey & Scott's 
diagnostic microbiological and biochemical methods, 
including appearance of bacterial colonies on culture 
medium, Gram staining, shape, motility, catalase, oxi-
dase, MR, VP, oxidative/fermentative (OF), indole, cit-
rate, urease, nitrate reduction, H2S, Gas, PYR, CAMP, 
gelatin, coagulase, bile solubility, DNase, fermentation 
of Fructose, Glucose and Lactose tests [17].
Susceptibility testing
Susceptibility testing was determined by disk diffu-
sion technique as described in the Clinical and Labo-
ratory Standards Institute (CLSI) guidelines [18], using 
Mueller Hinton medium (Himedia Company). Antimi-
crobial disks used in this study (purchased from Hime-
dia Company) were: Ciprofloxacin (5μg), Norfloxacin 
(10μg), Ofloxacin (5μg), Nalidixic acid (30μg), Amika-
cin (30μg), Ampicillin (10μg), Cefotaxime (30μg), Gen-
tamicin (10μg), Nitrofurantoin (300μg), Trimethoprim/
sulfamethoxazole (1.25/23.75μg), Cefoxitin (30μg), 
Meropenem (10μg), Cefepime (30μg), Ceftazidime 
(30μg), Cephalothin (30μg).
 Escherichia coli ATCC25922 was used as a quality con-
trol strain. Then the data were entered into Whonet 5.6 
(WHO, Geneva, Switzerland) software.
Preparation of bacterial DNA
Quinolone-resistant isolates (61 isolates) were cultured 
according to Baily & Scott's quantitative culture meth-
od [17] and cultured on Eosin Methylene Blue (EMB) 
and blood agar (BA) medium at the same time. DNA to 
be amplified was extracted from these isolates by boil-
ing. In this method, cell pellets were transferred to 50μl 
of distilled water in an eppendorf tube and incubated 
at 100°C for 10 min. After centrifuging of the lysate at 
6000×g for 10 min, the supernatant was stored at -20°C 
as a template DNA stock [19, 20].
PCR and DNA sequencing
Polymerase chain reaction (PCR) was performed by 
primer sequences designed for quinolone resistance-
determining region (QRDR) of gyrA and parC genes 
of E. coli isolates. Oligonucleotide primers for the PCR 
amplification in this study have been shown in Table I.
DNA was amplified using an initial denaturation step of 
5 min at 95°C, followed by 30 cycles consisting of 30 
seconds at 94°C, 30 seconds at the annealing tempera-
ture of 55°C and 58°C (for gyrA and parC, respectively) 
and 45 seconds at 72°C, and a final extension step of 
10 min at 72°C. PCR products were resolved by elec-
trophoresis on 1.2% agarose gel containing ethidium 
bromide. Afterward, among fluoroquinolone resistant 
E. coli strains, 13 isolates randomly selected for genet-
ic characterization of the QRDR of the parC and gyrA 
genes by sequencing process (Macrogene Company, 
Macrogen Inc., Seoul, Korea). E. coli ATCC25922 was 
used as a quality control for all PCR and sequencing 
reactions. After all, sequences were compared with the 
nucleotide sequence of the gyrA and parC genes in the 
GenBank database (accession numbers: FN554766.1 
and CP003034.1respectively). These data were analyzed 
using MEGA4 and Gene Runner softwares.
Results
Distribution of fluoroquinolones resistant E. coli strains 
was determined in different age and gender groups. 
Most resistant isolates were observed among outpatient 
adult women (Tab. II). Based on the results of our study, 
meropenem, cefoxitin, amikacin, nitrofurantoin and 
gentamicin showed the best activity against E. coli. Per-
centage of resistance to antimicrobial agents is shown 
in Figure 1. No resistance has observed to meropenem 
while ampicillin has shown the least activity against E. 
coli isolates. Among the inpatients individuals, 50% had 
a history of catheter utilization, and 57% had a history 
of surgery. 
A high resistance to three antibiotics ciprofloxacin, 
norfloxacin and ofloxacin was observed among strains 
(Fig. 1). Resistance rates to these three antibiotics were 
completely equal (45.2%). Out of the 135 E.coli iso-
lates, 61 strains were resistant to fluoquinolones and all 
fluoquinolones- resistant strains include gyrA and parC 
genes (Fig. 2).
After sequencing process, two mutations were de-
tected in the QRDR of gyrA gene, one at position 83 
Tab. I. Oligonucleotide sequences of primer sets for PCR.
Primer Sequence PCR Product Size(bp) Ref.
parC-F
parC-R
5′- TTCAGCGCCGCATTGTGTAT -3′
5′- GTTATGCGGTGGAATATCGGTC-3′
395 This study
gyrA-F
gyrA-R
5′-TTACACCGGTCAACATTGAGG -3′
5′- GACGACCGTTAATGATTGCC -3′
647 This study
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(Ser_Leu) and another at position 87 (Asp_Asn). Be-
tween 13 isolates of fluoroquinolone-resistance strains, 
11 isolates possessed these two mutations and 2 iso-
lates showed a single mutation (Ser83Leu) in the gyrA 
gene. Also, five different mutations were detected in 
parC gene of E. coli isolates, encoding Ser80Ile, Ser-
80Val, Ser80Arg, Glu84Val, and Gly78Ser. One isolate 
showed three mutations in parC; three isolates showed 
two mutations and the rest (six isolates) showed a sin-
gle mutation. On the other hand, three isolates showed 
no mutation in parC gene (Fig. 3). The mutations de-
tected in the QRDR of the gyrA and parC genes are 
shown in Table III.
The demographics and clinical characteristics of inpa-
tients are shown in Table IV. The number of inpatients in 
this study was 44, but due to a defect in the case of 4 pa-
tients, the information provided in this section is based 
on data from 40 inpatients. 
Tab. II. Age category.
Patients Sex Adult Pediatric Newborn
Inpatient 12 1 1
Outpatient Female 24 0 1
Inpatient
Male
10 1 0
Outpatient 11 0 0
Fig. 1. Antibiotic resistance pattern of E. coli isolates by CLSI disk diffusion methods.
CEP: Cephalothin, CTX: Cefotaxime, FOX: Cefoxitin, AMK: Amikacin, NAL: Nalidixic acid, NOR: Norfloxacin, STX: Trimethoprim/sulfameth-
oxazole, AMP: Ampicillin, CAZ: Ceftazidime, FEP: Cefepime, MEM: Meropenem, GEN: Gentamicin, CIP: Ciprofloxacin, OFX: Ofloxacin, NIT: 
Nitrofurantoin.
Fig. 2. a) PCR assay for the detection of gyrA gene. b) PCR assay for the detection parC gene.
a b
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Discussion
Mutations in the gyrA gene are the main cause of the 
resistance to fluoroquinolones. The most mutations have 
been shown to near the start region of the gyrA gene, 
known as the “QRDR”. This region encodes amino acid 
residues 67 to 106 in gyrA and the most common al-
terations occur at positions 83 and 87 [21, 22]. Topoi-
somerase IV is a secondary, less sensitive target for fluo-
roquinolone action in E. coli  [23]. On the other hand, 
alterations in the parC gene, correlate with reduced sus-
ceptibility to quinolones [24]. 
In the present study, two isolates of E. coli possessed a 
single mutation (in gyrA gene) and consequently they 
were susceptible to fluoroquinolones (ciprofloxacin, 
norfloxacin and ofloxacin), but were resistant to nali-
Fig. 3. Simultaneous alignment of partial gyrA and parC amino-acid sequences.
Tab. III. Location of mutations detected in gyrA and parC genes of Escherichia coli isolates.
Mutation
Isolate gyrA parC
83 84 85 86 87 78 79 80 81 82 83 84
Ser Ala Val Tyr Asp Gly Asp Ser Ala Cys Tyr Glu
E-1 Leu- ……- ……- ……- -Asn ……- ……- Ile- ……- ……- ……- ……
E-2 Leu- ……- ……- ……- -Asn ……- ……- Ile- ……- ……- ……- ……
E-3 Leu- ……- ……- ……- -Asn ……- ……- Ile- ……- ……- ……- Val
E-4 Leu- ……- ……- ……- -Asn ……- ……- Ile- ……- ……- ……- ……
E-5 Leu- ……- ……- ……- -Asn ……- ……- Val- ……- ……- ……- Val
E-6 Leu- ……- ……- ……- -Asn ……- ……- Ile- ……- ……- ……- ……
E-7 Leu- ……- ……- ……- ……- ……- ……- ……- ……- ……- ……- ……
E-8 Leu- ……- ……- ……- -Asn Ser- ……- Arg- ……- ……- ……- Val
E-9 Leu- ……- ……- ……- -Asn ……- ……- Ile- ……- ……- ……- ……
E-10 Leu- ……- ……- ……- -Asn ……- ……- Ile- ……- ……- ……- ……
E-11 Leu- ……- ……- ……- -Asn ……- ……- ……- ……- ……- ……- ……
E-12 Leu- ……- ……- ……- ……- ……- ……- ……- ……- ……- ……- ……
E-13 Leu- ……- ……- ……- -Asn ……- ……- Ile- ……- ……- ……- Val
E-14 ……- ……- ……- …… ……- ……- ……- ……- ……- ……- ……- ……
E-14: quality control (Escherichia coli ATCC25922).
Tab. IV. Demographic and clinical characteristics for urinary tract in-
fection in inpatients (n = 40).
Characteristics No of inpatient (%)
Female 21 (52.5)
Male 19 (47.5)
History of previous urinary 
tract infection
3 (7.5)
Antibiotic use in the last 3 
months
16 (40)
Catheter 23 (57.5)
Catheter history 20 (50)
Surgical history 23 (57.5)
History of admission 13 (32.5)
History of surgery in the last 
12 months
11 (27.5)
Prostate enlargement 3 (7.5)
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dixic acid. These findings are in agreement with other 
studies, indicating that nalidixic acid could be used as 
a good marker for a single mutation by use of the disk 
diffusion method [25-28]. 
Another 11 isolates showed different mutations in gyrA 
and parC genes and were resistant to fluoroquinolones. 
This confirms that multiple mutations are necessary to a 
great extent for the high level of quinolone resistance [26]. 
Our study has several limitations, including; first, the 
number of sequencing isolates were too small for a de-
finitive evaluation. Second, we have examined just two 
genes of E. coli isolates. Several studies have shown a 
correlation between gyrB and/or parE and FQ resistance 
in E. coli [29]. Also efflux pump genes can be a cause of 
FQ resistance.
 In the present study, we determined antimicrobial resis-
tance pattern (by focus on fluoroquinolones) of E. coli 
isolates from a university medical center, Alzahra Hospi-
tal, Isfahan, Iran. Generally, empirical therapy of patients 
with UTIs begins with extended-spectrum antibiotics (it 
often consists of FQ, especially ciprofloxacin). These 
treatments before the final microbiological results lead 
to the increased resistance and emergence of resistant 
strains. According to the type and method of taking anti-
biotics in each country, there is a considerable difference 
in susceptibility and resistance to antimicrobial agents in 
E.coli causing urinary tract infections [30]. For the hospi-
talized patients with urinary tract infections, 57% used the 
catheter during admission, 50% had a history of using the 
catheter and 57% had a history of surgery. It is possible 
that these factors can increase the risk of urinary tract in-
fections, if validated by proper risk factors analyses.
This study has shown a significant high resistance to 
fluoroquinolones in respect of other surveys in differ-
ent regions of Iran and different countries in Europe. 
These findings serve as a warning that resistance to fluo-
roquinolone is increasing quickly. As fluoroquinolones 
are the most important used antimicrobial agent in the 
treatment of UTIs in Iran, increasing resistance to these 
agents has caused concern to relevant treatment of these 
infections. There are different resistance mechanisms to 
FQ. One of them is mutations that alter the drug targets. 
We observed different mutations in the QRDRs of grain 
and pores that cause a great effect on FQ resistance. By 
doing more research on the molecular basis of FQ resis-
tance, new therapeutic strategies will create for FQ-re-
sistant E. coli. With regard to the continuous changing in 
antibiotic sensitivity pattern, we recommend a guideline 
for physicians, which could determine bacterial sensitiv-
ity in populations yearly and choose the correct empiri-
cal treatment according to these patterns.
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